Stifel on SpyGlass Pharma (SGP): complete enrollment indication reinforces approval confidence
Tweet Send to a Friend
Stifel analyst Tom Stephan reiterated a Buy rating and $42.00 price target on SpyGlass Pharma (NASDAQ: SGP)The analyst commented, "Alongside ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
